<DOC>
	<DOCNO>NCT02124122</DOCNO>
	<brief_summary>This Phase 1 study ass safety tolerability Lactobacillus reuteri ( Lr ) strain DSM 17938 healthy child Peru . It preliminary study support clinical trial ass safety efficacy L. reuteri treatment pediatric diarrhea Peru .</brief_summary>
	<brief_title>Safety Lactobacillus Reuteri Healthy Children Ages 2 5 Years Peru</brief_title>
	<detailed_description>This phase I blind randomize study safety tolerability Lactobacillus reuteri DSM 17938 give daily period five consecutive day . Upon enrollment subject randomize one two treatment group ratio treatment placebo 2:1 . Subjects randomize receive either : A. Lactobacillus reuteri ( Lr ) : 108 ( 100 million ) organism Lactobacillus reuteri per dose , give daily five-day treatment period corresponds dose closely related L. reuteri ATCC 55730 strain show therapeutic infantile colic . The strain use study ( DSM 17938 ) cure antibiotic resistance plasmid find original BioGaia strain ( L. reuteri ATCC 55730 ) . B . Placebo oil preparation , administer 5 drop oil vehicle use manufacturing Lr suspension , give daily five-day study period ( BioGaia AB , Stockholm , Sweden ) . In first 30 subject randomize , administration dose study preparation drop ( A B ) immediately follow offer 2 ounce flavored PediaSure ® ( Abbott Laboratories ) nutritional supplement child . The second 30 subject enrol offered PediaSure ® product administration . This format also allow u assess impact concurrent administration buffer non-lactose contain formula prebiotic nutritional property intestinal colonization L. reuteri PCR .</detailed_description>
	<criteria>Children age 25 year exclusion criterion 1 ) No enrollment family member household follow present : 1 . Another study participant household 2 . Pregnancy current breastfeeding household member 3 . Presence infant age 6 month live household 4 . Presence immune suppress individual use immunosuppressive agent ( include limited corticosteroid methotrexate , etc . ) household member 5 . Presence serious congenital anomaly chronic medical condition opinion investigator would contraindicate participation household member , include history gastrointestinal surgery , chronic gastrointestinal illness , abnormal intestinal anatomy , abnormal bowel functionality 2 ) Allergy penicillin cephalosporin gentamicin 3 ) History antibiotic use last 30 day 4 ) Use probiotic product within past 90 day , include masato ( local product ferment bacteria ) yogurt product contain live bacterial culture . 5 ) History diarrheal illness within past 30 day 6 ) Presence fever preexist adverse event monitor study 7 ) Positive result serum diagnostic test antibody HIV . Testing Hepatitis B core antigen , Hepatitis C necessary child adult , since universal vaccination Hepatitis B among child community , form hepatitis rare largely asymptomatic age group . 8 ) Presence severe anemia , define serum hemoglobin &lt; 8 gm/dL 9 ) Out range laboratory value test monitor potential adverse event , describe Appendix 2 , B . LABORATORY VALUES , detect base Day 0 blood test result . However , subject exclude base serum hemoglobin meet exclusion criterion 8 . 10 ) Preenrollment stool sample ( collect within 14 day Day 1 study ) positive L. reuteri PCR .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Focus</keyword>
	<keyword>safety</keyword>
</DOC>